Analysts Update Their Estimates For Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) concluded the trading at $21.09 on Wednesday, March 20 with a fall of -0.42% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $21.18 and 5Y monthly beta was reading -0.85. Considering stock’s 52-week price range provides that FUSN hit a high price of $21.21 and saw its price falling to a low level of $2.31 during that period. Over a period of past 1-month, stock came adding 56.69% in its value.

With its current market valuation of $1.53 billion, Fusion Pharmaceuticals Inc is set to declare its quarterly results on May 09, 2024 – May 13, 2024. Analysts are in estimates of -$0.34 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.45 for 2023 with estimates of that growing to -$1.38 in next year. These estimates are suggesting current year growth of 27.50% for EPS and 4.80% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $410k. The average estimate is representing an increase of 192.90% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $2.22 million in 2023, which will be 52.00% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review FUSN stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.

Digging deeper we become aware of the PEG ratio of the FUSN stock which is currently positioned at 0. It further provides that stock’s current price level is 83.08% away from its 20-day simple moving average and is 92.43% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 83.44 while volatility remained at 5.43% over the past week which changes to 7.67% when measuring it over the past month. Beta is valued at -0.83, while measure of average true range or ATR is currently at 1.45.

Having a second look at Fusion Pharmaceuticals Inc (NASDAQ:FUSN) provides that stock’s average daily trading volume for 3 months was 1.95 million, while it jumped to 6.34 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 72.41 million.

The percentage of outstanding shares held by the insiders is 34.09% while it is 58.60% for the institutional holders. The figures also indicate that as of Feb 29, 2024, number of stock’s short shares was 8.64 million which implies a short ratio of 6.75. This shows up a 11.93% of Short Interest in company’s outstanding shares on the day. In February the standing of shares short improved as it was 4.19 million in the previous month. Addition of 119.46% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Most Popular